Clinical trials
Prostate Cancer Metastatic Disease clinical trials
Below are recruiting prostate cancer metastatic disease clinical trials, each written for real people, not researchers. We’re tracking 605 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03903835RecruitingPhase 3
Biomarker-guided treatment for metastatic prostate cancer
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
AalstAges 18 years+ - NCT06480110RecruitingPhase 1/Phase 2
Ebastine plus docetaxel for advanced prostate cancer
This trial tests if combining the allergy drug ebastine with the chemotherapy docetaxel can help men with advanced prostate cancer that has stopped responding to hormone therapy. It may offer a new treatment option for those whose cancer is still growing.
CopenhagenAges 18 years+ - NCT07206056RecruitingPhase 1/Phase 2
Study of tulmimetostat and luxdegalutamide for advanced prostate cancer
This trial tests a new combination of two drugs for men whose prostate cancer has spread and is no longer controlled by hormone therapy. The study aims to see if this treatment can help shrink tumors or slow the disease.
Denver, ColoradoAges 18 years+ - NCT06702995RecruitingPhase 1/Phase 2
Study of XNW5004 plus enzalutamide for advanced prostate cancer
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
Jinan, ShandongAges 18 years+ - NCT07197671RecruitingPhase 1
Radiation drug for people with head and neck cancer on immunotherapy
This study tests a radioactive drug called Y-NM600 that may help treat head and neck cancer that has spread. It is given to people who are already receiving an immunotherapy drug (like Keytruda or Opdivo) and whose cancer is stable or slightly growing.
Madison, WisconsinAges 18 years+ - NCT07200830RecruitingPhase 3
Testing different schedules of a targeted radiation drug for advanced prostate cancer
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
Anchorage, AlaskaAges 18 years+ - NCT07190300RecruitingPhase 1/Phase 2
Study of tulmimetostat plus other hormone therapies for metastatic prostate cancer
This study tests two different combinations of drugs for men with prostate cancer that has spread to other parts of the body but still responds to hormone therapy. It compares a new pill (tulmimetostat) combined with standard treatments like darolutamide or abiraterone to see if it can help control the cancer longer.
Birmingham, AlabamaAges 18 years+ - NCT07192614RecruitingPhase 1/Phase 2
Study of AZD6621 for men with advanced prostate cancer
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
Orlando, FloridaAges 18 years+ - NCT07189403RecruitingPhase 1
Study of DS9051b for adrenal cancer and prostate cancer
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
Sarasota, FloridaAges 18 years+ - NCT07182279RecruitingPhase 1/Phase 2
Internal radiation before prostate surgery for high-risk cancer
This trial tests a treatment approach for newly diagnosed, high-risk prostate cancer. You would receive a short course of internal radiation (high-dose-rate brachytherapy) before surgery to remove your prostate. The goal is to see if this combination is safe and works better than surgery alone.
Houston, TexasAges 40 years+ - NCT07179783RecruitingPhase 2
Sacituzumab Tirumotecan and Tagitanlimab for aggressive prostate cancer
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07181161RecruitingPhase 1/Phase 2
Testing a new drug for metastatic prostate cancer
This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.
Fayetteville, ArkansasAges 18–130 - NCT07156045RecruitingEarly Phase 1
Study of donor NK cells targeting PSMA for advanced prostate cancer
This trial tests a new treatment using natural killer cells from a healthy donor that are designed to find and attack prostate cancer cells that have a protein called PSMA. It may help men with advanced prostate cancer that has stopped responding to hormone therapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07164443RecruitingPhase 3
Study of Pasritamig with or without JNJ-87189401 for advanced prostate cancer
This study tests a new combination therapy for advanced prostate cancer that has stopped responding to standard treatments. It aims to see if the combination is more effective than placebo in slowing the cancer's growth.
La Jolla, CaliforniaAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07145177RecruitingPhase 1
Lu177-PSMA with liver treatment for advanced prostate cancer
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
San Francisco, CaliforniaAges 18 years+ - NCT07140900RecruitingPhase 1
Study of xaluritamig combined with hormone therapy for advanced prostate cancer
This trial tests a new drug, xaluritamig, given with standard hormone therapy for men with prostate cancer that has spread to other parts of the body (metastatic) and is still sensitive to hormone therapy. It aims to see if the combination is safe and works better than hormone therapy alone.
San Francisco, CaliforniaAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT07115914Recruiting
PSMA PET scan to monitor prostate cancer after focal therapy
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
Chicago, IllinoisAges 18 years+ - NCT07112599Recruiting
AI predicts lymph node spread in high-risk prostate cancer
This study uses artificial intelligence to examine MRI and other health data to better predict if high-risk prostate cancer has spread to nearby lymph nodes. Researchers hope this will help guide treatment decisions.
Hefei, AnhuiAges 50 years+ - NCT07111507RecruitingPhase 2
Tarlatamab for advanced prostate cancer
This trial tests a drug called tarlatamab for people with advanced prostate cancer that has a specific protein (DLL3) on their tumor cells. The goal is to see if tarlatamab can help shrink or slow the cancer.
San Diego, CaliforniaAges 18 years+ - NCT07112781Recruiting
Single dose radiation for early prostate cancer
This trial tests whether a single, high dose of radiation can treat low- to intermediate-risk prostate cancer. It may be a shorter and more convenient option for eligible patients.
MoscowAges 18 years+ - NCT07112209Enrolling by invitation
Rezvilutamide plus chemo for prostate cancer
This study tests a new combination treatment (Rezvilutamide plus docetaxel chemotherapy) for men with advanced prostate cancer that has stopped responding to abiraterone. The goal is to see if this combination can help control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07103018RecruitingPhase 1
Study of KTX-2001 for men with advanced prostate cancer
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
San Francisco, CaliforniaAges 18 years+
Hear when a new Prostate Cancer Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer metastatic disease?
- Yes. Clin2 currently lists 605 recruiting prostate cancer metastatic disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer metastatic disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer metastatic disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.